about
Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura.Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United StatesClinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 daysINTERCEPT pathogen-reduced platelets are not associated with higher rates of alloimmunization with (or without) clinical refractoriness in published studiesAmustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemiaAcute Zika virus infection in an asymptomatic blood donor at the onset of the Puerto Rico epidemicPreclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathioneTransfusion of pathogen-reduced platelet components without leukoreduction
P50
Q54203043-525EC6AB-03CA-46D0-B765-044844189606Q90026749-FD290286-E267-4FAD-AF18-23D95CE0935CQ90414824-670B196B-B13E-4608-AA38-E5C63838DA8AQ91558744-2D62A1CC-D2CC-41DB-93FE-C35B0761B54DQ92424160-1E5AE61A-D8E0-47FC-8E8C-49C58DF55414Q92588510-9F38B572-747E-48C3-B541-C56B6D9C0A97Q92597042-26349F58-1C4D-4999-BD47-7CE46538719CQ92665721-79A81E19-A459-4249-A553-13761BA3DF7E
P50
description
researcher
@en
name
Laurence Corash
@en
type
label
Laurence Corash
@en
prefLabel
Laurence Corash
@en
P31
P496
0000-0002-8615-9869